Skip to Content

Reduction of Pain, Itching, and Rash Shown in Study of Oncology Patients by MPM Medical, Inc., Subsidiary of RBC Life Sciences

IRVING, Texas--(BUSINESS WIRE)--May 29, 2008 - MPM Medical, Inc., today announced that a peer-reviewed clinical research study of its proprietary product Regenecare(R) showed effective reduction in severe burning, itching, and rashes, adverse side effects suffered by patients treated with frequently used anti-cancer drugs known as EGFR (Epidermal Growth Factor Receptor) inhibitors. The study was presented at the 33rd Annual Oncology Nursing Society Congress held in Philadelphia, PA this past weekend and attended by approximately 5,000 oncology nurses.

Paul R. Miller, President of MPM Medical, stated, "Over 85% of patients treated with EGFR inhibitors develop red rashes which can cause such pain and embarrassment that some patients stop the treatment. In the past, products to relieve these skin conditions have not been available. We are pleased to be able to show oncology nurse specialists from across the country that their patients don't have to live with the pain caused by EGFR anti-cancer treatment."

MPM Medical, Inc., a wholly-owned subsidiary of RBC Life Sciences, Inc. (OTCBB: RBCL), develops and markets proprietary prescription and nonprescription products for wound and pain management, sold through medical-surgical dealers to nursing homes, hospitals and cancer clinics.

The statements above, other than statements of historical facts, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.


Halliburton Investor Relations
Geralyn DeBusk, 972-458-8000
Chase Zavoina, 972-458-8000
Deidra Roy, 972-458-8000

Posted: May 2008